{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:32:14Z","timestamp":1778283134345,"version":"3.51.4"},"reference-count":15,"publisher":"BMJ","issue":"e3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2023,7,4]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>People with Parkinson\u2019s disease (PwP) have a high palliative symptom burden throughout their disease course, equivalent to advanced malignancy. We aim to establish trends in symptom frequency and prescribing in the 72 hours prior to death for PwP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective case note review of PwP who died between February 2019 and September 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>51 patients were included. 60.78% of patients (n=31) had agitation and 58.82% (n=30) had pain in the final 72 hours. Patients with cognitive impairment were 4.67 times more likely to experience agitation (p=0.035) compared with those without, with higher total midazolam doses (29.18 mg vs 11.4 mg, p=0.21). Terminal motor symptoms were recorded in three patients. 28.57% of patients received the recommended dose of rotigotine for dopaminergic therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PwP have a significant symptom burden at the end of life (EOL) with levels of terminal agitation at the higher end of those expected in the general population. There was a trend towards higher doses of sedation, rather than analgesia, in people with coexistent cognitive impairment.<\/jats:p><jats:p>Terminal stiffness, despite being seldom documented in the literature, is an important although infrequent symptom.<\/jats:p><jats:p>Rotigotine use at EOL remains commonplace and better understanding of its effect and dosing is required.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2023-004389","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:15:51Z","timestamp":1689725751000},"page":"e912-e915","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Parkinson\u2019s disease: symptoms and medications at the end of life"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5122-3030","authenticated-orcid":false,"given":"Elisabeth Alice","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"King-Oakley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2305-4154","authenticated-orcid":false,"given":"Edward William","family":"Richfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"2024121022580576000_13.e3.e912.1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000746"},{"key":"2024121022580576000_13.e3.e912.2","doi-asserted-by":"crossref","unstructured":"Miyasaki JM , Long J , Mancini D , et al . Palliative care for advanced Parkinson disease: an interdisciplinary clinic and new scale, the ESAS-PD. Parkinsonism Relat Disord 2012:S6\u20139. doi:10.1016\/j.parkreldis.2012.06.013","DOI":"10.1016\/j.parkreldis.2012.06.013"},{"key":"2024121022580576000_13.e3.e912.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(03)00074-5"},{"key":"2024121022580576000_13.e3.e912.4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/ageing\/afaa256","article-title":"Rotigotine patch prescription in inpatients with Parkinson\u2019s disease: evaluating prescription accuracy, delirium and end-of-life use","volume":"50","author":"Ibrahim","year":"2021","journal-title":"Age Ageing"},{"key":"2024121022580576000_13.e3.e912.5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40261-021-01054-1","article-title":"Idiopathic Parkinson\u2019s disease at the end of life: a retrospective evaluation of symptom prevalence, pharmacological symptom management and transdermal rotigotine dosing","volume":"41","author":"Hindmarsh","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2024121022580576000_13.e3.e912.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111823","article-title":"Validation of a consensus method for identifying delirium from hospital records","volume":"9","author":"Kuhn","year":"2014","journal-title":"PLoS One"},{"key":"2024121022580576000_13.e3.e912.7","doi-asserted-by":"crossref","DOI":"10.1186\/s42466-021-00157-6","article-title":"An updated calculator for determining levodopa-equivalent dose","volume":"3","author":"Nyholm","year":"2021","journal-title":"Neurol Res Pract"},{"key":"2024121022580576000_13.e3.e912.8","unstructured":"Calculator O . A guideline for the OPTIMAL management of patient\u2019s with Parkinson\u2019s disease; 2022."},{"key":"2024121022580576000_13.e3.e912.9","unstructured":"Wilcock A , Howard P , Charlesworth S , eds. PCF7: palliative care formulary. London: Pharmaceutical Press, 2020."},{"key":"2024121022580576000_13.e3.e912.10","doi-asserted-by":"publisher","DOI":"10.1177\/1049909112468222"},{"key":"2024121022580576000_13.e3.e912.11","doi-asserted-by":"publisher","DOI":"10.1177\/0269216317726443"},{"key":"2024121022580576000_13.e3.e912.12","doi-asserted-by":"publisher","DOI":"10.1177\/1049909114559069"},{"key":"2024121022580576000_13.e3.e912.13","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-012-0938-8"},{"key":"2024121022580576000_13.e3.e912.14","doi-asserted-by":"publisher","DOI":"10.1002\/gps.995"},{"key":"2024121022580576000_13.e3.e912.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2012-000412"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2023-004389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T07:12:41Z","timestamp":1733901161000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2023-004389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":15,"journal-issue":{"issue":"e3","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/spcare-2023-004389"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2023-004389","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]}}}